The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Genomic Biomarker Market Expected To Change From 2026 To 2030?
The genomic biomarker market has seen rapid expansion in recent years. Its valuation is anticipated to increase from $9.9 billion in 2025 to $11.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.8%. This historical surge in growth is primarily linked to factors such as greater investment in genomic research, the expansion of biomarker studies focused on oncology, enhanced access to next-generation sequencing technologies, increased collaboration between diagnostic and pharmaceutical companies, and the early adoption of personalized medicine approaches.
The genomic biomarker market is projected to experience substantial expansion in the coming years. Its valuation is set to reach $22.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.5%. This anticipated growth during the forecast period stems from factors such as the escalating demand for precision medicine therapies, the increasing integration of biomarkers into drug development processes, the wider adoption of companion diagnostics, a heightened emphasis on early disease detection, and strengthened regulatory backing for biomarker-driven approvals. Key trends anticipated over the forecast timeframe encompass the expanding uptake of predictive genomic biomarkers, the growing prevalence of pharmacogenomic testing, the deeper incorporation of genomic data into clinical decision-making, the broadening scope of biomarker-based oncology diagnostics, and an intensified focus on clinical validation benchmarks.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp
Which Major Drivers Are Influencing The Expansion Of The Genomic Biomarker Market?
The expanding occurrence of chronic illnesses is anticipated to fuel the expansion of the genomic biomarker market in the future. These are enduring health conditions that persist and typically develop gradually. The rising incidence of these diseases stems from an aging global populace and a surge in lifestyle-related ailments like obesity and diabetes. Genomic biomarkers facilitate prompt diagnosis and customized preventive measures for chronic diseases by pinpointing genetic susceptibilities and adapting treatments. Such a forward-thinking method contributes to lowering prevalence by targeting vulnerable individuals prior to the onset of the disease. For example, in September 2023, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, reported that chronic diseases are responsible for 41 million deaths globally each year, constituting 74% of all fatalities. This total encompasses 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the expanding occurrence of chronic illnesses is a key driver for the growth of genomic biomarkers.
How Is The Genomic Biomarker Market Organized By Segment Classification?
The genomic biomarker market covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users
Subsegments:
1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction
2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis
What Trends Are Transforming The Genomic Biomarker Market?
Key companies operating within the genomic biomarker market are concentrating on developing sophisticated products, such as advanced liquid biopsy assays, to enable thorough genomic profiling of solid tumors. A liquid biopsy assay serves as a diagnostic test that scrutinizes genetic material, typically circulating tumor DNA (ctDNA), from a blood sample to both detect and monitor cancer. The identification of genomic biomarkers can furnish insights into specific mutations, gene expression profiles, or other genetic alterations associated with cancer. For instance, in November 2023, Illumina Inc., a US-based biotechnology company, launched an advanced liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), specifically for comprehensive genomic profiling of solid tumors. This assay offers enhanced analytical sensitivity by identifying low-frequency variants with just 20 ng of cell-free DNA, a decrease from 30 ng. It provides results in under four days, considerably speeding up genomic profiling compared to conventional techniques. Its streamlined workflow and impending automation will simplify lab integration and elevate efficiency.
Who Are The Industry Participants Involved In The Genomic Biomarker Market?
Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.
Get The Full Genomic Biomarker Market Report:
https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report
Which Region Has The Greatest Market Share In The Genomic Biomarker Market?
North America was the largest region in the genomic biomarker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Genomic Biomarker Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report
Browse Through More Reports Similar to the Global Genomic Biomarker Market 2026, By The Business Research Company
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Renal Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
Cancer Biomarker Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model